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In the treatment of adult attention-deficit/hyperactivity disorder (ADHD) the importance
of psychological interventions in combination with pharmacotherapy is widely accepted
in contemporary clinical routine. The natural course of the disorder seems to justify
additional psychological interventions because even in patients who are highly compliant
to pharmacotherapy full remission is not always achieved. The aim of the present
study was to analyze the contribution of psychotherapy to the treatment of adult
ADHD patients. In a randomized controlled study, the efficacy of a combined treatment
of psychotherapy with pharmacotherapy is compared to pharmacological intervention
alone. After initiation and stabilization of treatment with methylphenidate (MPH) in all
subjects randomization to the two different treatment conditions was done. Afterwards
both groups underwent treatment for about 10–12 weeks, the experimental group
receiving sessions of cognitive-behavioral therapy (CBT) whereas the control group only
receivedmedication and standard clinical management (SCM). ADHD symptoms differed
statistically during time but not between the two different treatment conditions. This result
was the same for the single ADHD symptoms—inattention, hyperactivity, impulsivity, and
emotional symptoms—and also for impairment. Individual standardized ADHD specific
CBT program was not able to outperform SCM.
Keywords: ADHD, cognitive-behavioral therapy, multimodal therapy, pharmacotherapy, standard clinical
management, adulthood
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INTRODUCTION
Attention-deficit/hyperactivity disorder (ADHD) beginning in
childhood has been accepted to persist in ∼50% of cases into
adulthood (1). With a worldwide prevalence between 2.5 and
4.4% (2–4) ADHD is a frequent disorder in adulthood. The
disorder is characterized by the core symptoms inattention,
impulsivity, and hyperactivity (5–7), and additional symptoms
such as emotional dysregulation [see (8)]. These symptoms have
often a substantial impact on daily functioning leading to severe
impairment in different domains of life (9, 10). According to
guidelines (11–13) psychopharmacological treatment is the first
line treatment in adult ADHD, but a multimodal approach is
generally recommended, involving educational aspects about the
disorder and psychotherapy addressing concomitant problems
(12–14).
ADHD is a multi-factorial disorder that is associated with a
tremendous financial burden, increased stress to families, and
adverse academic and vocational outcomes (15). Across the
life span, the social and societal costs of untreated ADHD are
considerable. Many adults with ADHD display frequent changes
in employment, academic underachievement, poor planning
abilities, messiness, dangerous driving, and instable relationships
or tend to social isolation and engagement in leisure activities that
are highly absorbing or stimulating and hazardous (16). They also
express difficulties in housekeeping and managing their children
(17). ADHD is also a common and costly condition affecting
performance at work. In a national representative sample of
workers in the USA a total of 4.2% suffer from ADHD which
results in 35 days of annual lost work performance (18). Finally,
it is important to mention that for an ADHD diagnosis in
adults functional impairment in domains of life is required
and psychotherapy may be decisive in the management of the
mentioned functional impairment (19).
Psychotherapeutic treatment of adult ADHD is considered
as part of a comprehensive multimodal therapy program which
is based on pharmacological treatment. According to NICE
(12, 13) pharmacological and psychotherapeutic treatments
are both possible interventions. Although the importance of
psychotherapy is continuously emphasized, controlled studies
to support this claim are still scarce and the effectiveness of
psychotherapy in adult ADHD is partly inconsistent. Therefore,
the level of evidence (III, recommendation level C) is still
inconsistent. Moreover, there are no scientific criteria available to
determine in which cases a combined therapy is more effective
than exclusive pharmacotherapy since studies on this topic
are still lacking (evidence level IV, recommendation level D).
Nevertheless, the guidelines recommend to combine the two
forms of therapy since some symptoms are more accessible by
psychotherapy (e.g., organizational and social behavior) whereas
other symptoms respond more readily to medication (e.g.,
attention, emotional instability) [see (12, 13)].
Multimodal treatment including behavioral therapy and
medication has been found to be most effective in treating
children with ADHD (16). The Multimodal Treatment of
Attention Deficit Hyperactivity Disorder (MTA) study likewise
documented that a comprehensive behavior therapy program is
also effective, albeit less than medication. A multimodal program
which combined medication and behavioral interventions results
in the greatest overall improvement (20). According to Kordon
and Kahl (21) the rationale for multidimensional therapy is
again a differential response of symptoms to various treatment
strategies which implies that not all symptomatic areas can
be improved by a pharmacological treatment alone. For
example, compliance and permanent changes in behavior can
be improved by means of detailed psychoeducation for the
patient and his family. Furthermore, in many patients comorbid
disorders are present which must be considered adequately
in therapy. Recommendations in the literature usually suggest
cognitive-behavioral interventions (22). Occasionally analytically
orientated approaches are mentioned often focusing on rather
secondary aspects of the disorder such as the frequently present
problem of low self-esteem. Recommendations in the literature
favor almost exclusively the application of cognitive-behavioral
interventions [e.g., (23, 24)]. Different authors [e.g., (25)]
point explicitly at the fact that unstructured interventions are
ineffective in ADHD patients due to frequent neuropsychological
deficits caused by the disorder itself. Difficulties in executive
functioning resulting in lack of focusing and problems with
memory, and difficulties in the task performance ask for a
structured psychotherapeutic approach.
With regard to the indication for psychotherapy specific
arguments stem from studies on the course of ADHD on the
one hand and from the results of pharmacological studies on
the other hand. With regard to the course of ADHD Ramsay
and Rostain (26) state: “rather than ‘growing out of ’ ADHD, the
symptoms seem to ‘grow with’ the individual” (p. 320). In the
same way Biederman et al. (27) report in their study on the course
of ADHD in children that at the transition to adulthood very
different presentations of the disorder are distinguishable. Apart
from a so-called “syndromatic remission” (<8 of the 14 possible
DSM-III-R criteria) they distinguish a “symptomatic remission”
(<5 symptoms, so-called subthreshold) and a “functional
remission” (<5 symptoms and no functional impairments).
Depending on the definition a different quantity of patients
showed remarkable impairments. Especially in attention-deficits
the relatively lowest improvements were observed. Moreover,
it is assumed that not all changes appear simultaneously.
Symptoms tend to get better within weeks, functioning gets
better within months and—perhaps most important—careful
observation may identify changes in development taking place
over years. Therefore, psychosocial treatment is helpful to reduce
any residual impairment (28).
Psychopharmacological studies put the emphasis on the
convincing efficacy of methylphenidate [MPH, e.g., (29)], but
they also show that in some patients efficacy is low or medication
is refused (19, 30). Treatment denial may be a consequence
of a lack of proper attitude or depend on a general opinion
concerning medication or possibly is the result of side effects. In
addition, pharmacotherapy despite of its verified efficacy is not
consistently positive assessed. Lower creativity levels in everyday
life or a changed perception of oneself and others are sometimes
newly emerging problems (31). Responder rates ofMPH in adults
as reported in literature vary from 25 to 78% (32) and emphasize
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that a big number of patients, if not even all of them, still have at
least some persisting symptoms at the end of their therapy.
Furthermore, due to the persistence of ADHD symptoms
various problems in different areas of functioning arise (e.g.,
family and social life, work, and organization). Even in the
case of an excellent therapeutic response these problems do not
disappear immediately. Demoralization caused by long lasting
disappointment and reoccurring frustration is frequently present
and has to be considered in therapy (33). Based on clinical
observations and reports from affected people some ADHD
patients wish to be treated by other means than medication by
receiving additional help which often results in essential and
ongoing changes in everyday life (19). Self-esteem is—as already
mentioned—frequently affected by the long-lasting problems
caused by ADHD. Relevant targets for psychotherapy are found
in the following areas which are associated with the disorder itself
[e.g., (34)]: area of performance, social and interpersonal area,
and problems with adaptive behavior.
Despite of the continuous general demand for multimodal
treatment, the data presented are still insufficient. An important
element of almost all existent studies is pharmacological
treatment usually with MPH which is in accordance with today’s
state of knowledge. Psychotherapy on its own does not seem to
be as efficacious as pharmacotherapy which is comprehensible
considering the current knowledge about etiology and pathology
of this disorder.
Cognitive-behavioral therapy (CBT) shows some evidence
in the psychological treatment of ADHD. Different un- and
controlled CBT studies reported some treatments effect like
ADHD symptom reduction [e.g., (24, 35–39)]. A review and
meta-analyses of nine randomized controlled trials showed that
CBT for adult ADHDwas superior to waiting list with amoderate
to large effect size (SMD = 0.76, 95% CI [0.21, 1.31], p = 0.006)
and superior to active control groups with a small to moderate
effect size (SMD = 0.43, 95% CI [0.14, 0.71], p = 0.004) in
reducing ADHD symptoms post-intervention (40).
In conclusion, recent empirical data about psychotherapeutic
treatments of patients with ADHD indicate that psychotherapy
might be efficacious in the treatment of adult ADHD. However,
it is not possible at the present time to give a concluding
appraisal of the efficacy of a combined pharmacological
and psychotherapeutic intervention in comparison to a
purely pharmacological treatment due to major deficits of
studies. Trying to summarize the problems of the studies,
two problem areas can be identified: problems concerning
content and concepts (e.g., selection of particular therapeutic
components often not justified sufficiently, often manuals
are missing or too general and not enough standardized,
components which are also applicable for group settings are
often not much individualized), and problems concerning
methodological aspects [non-randomized controlled study,
diagnostic interviews not standardized (ADHD and comorbid
conditions), comorbidity not recorded, pharmacotherapy not
controlled or not standardized, control groups missing, control
groups without controlling relevant variables (e.g., contact time
with mental health services), treatment response limited to self-
report instruments, rarely multimodal assessment, assessment of
post-treatment outcome only, no follow-up period to investigate
maintenance of outcome].
General aim of the study was to evaluate the contribution of
psychotherapy to the treatment of adult ADHD patients. The
primary objective of the randomized controlled study was to
evaluate the efficacy of multimodal therapy (treatment group:
medication + psychotherapy) compared with medication alone
(control group: medication) in adult subjects with ADHD. We
expected that the multimodal treatment shows a greater success
in treatment than medication alone. Secondary objectives were:
assessment of the stability of the change in follow-up, assessment
of the benefits with regard to impairments in daily life, and
assessment of the quality of the psychotherapy.
METHODS
Subjects
A total of 50 individuals who came to the ADHD Special
Consultations Unit of the Outpatient Department of the
University of Basel Psychiatric Clinics (UPC) between 2010 and
2015 were recruited for this randomized controlled study. Five
men and two women dropped out before being randomized to
one of the two treatment groups. Finally, the data of 43 ADHD
patients were analyzed.
Male and female patients with a diagnosis of ADHD according
to DSM-IV criteria, with symptoms before 7 years that continue
to meet these criteria at the time of assessment, were enrolled
in the study. ADHD was not diagnosed if the symptoms were
better accounted for by another psychiatric disorder (e.g., mood
disorder). All individuals fulfilled all general criteria for a
treatment with MPH in accordance with the existing guidelines
(12, 13) and preconditions of psychotherapy (sufficient language
skills, appropriate intellectual level corresponding to clinical
impression). Comorbid psychiatric disorders were allowed, if the
subject was in a stable clinical condition and/or has been on a
stable dosage for at least 3 months prior to screening.
Subjects with clinically significant unstable medical or
neurological conditions like hypertension and other cardiac
diseases, hyperthyroidism, epilepsy, tic-disorder, or any other
severe somatic disorder were excluded from the study. Also,
individuals with unstable psychiatric disorders apart from
ADHD like moderate to severe mood or anxiety disorders,
schizophrenia, with an addiction to or abuse of cocaine, heroin,
or other opioids, designer drugs, tranquilizers, other sedatives, or
alcohol, and those consuming THC more than two joints a week
or more than eight joints a month were also excluded. Addiction
to or abuse of nicotine and/or caffeine were documented but
were not exclusion criteria. Acute psychiatric symptoms like
suicidality, psychotic exacerbations, manic episode, known non-
response or allergy to MPH, pregnant, or breast-feeding women
were also exclusion criteria. Finally, individuals who received
CBT within the last 2 years could not participate in the study.
Study Design and Procedure
All subjects presenting to obtain a diagnosis, underwent a
comprehensive diagnostic assessment to assess the existence of
the diagnosis of adult ADHD and possible comorbid disorders
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(see Figure 1). After confirmation of diagnosis and signature
of informed consent to participate in the study, treatment
was initiated with MPH since MPH has been considered to
be the treatment of first choice for ADHD [see (32)], as
shown in several empirical studies [e.g., (41)] as well as a
meta-analysis (29). This is also stated in general reviews or
guidelines [e.g., (11–13)]. Other concomitant medication was
only allowed if the subject had been on a stable dosage
for more than 3 months prior to screening. Up-titration of
MPH was considered successful if there was a response of
at least 30% in the CAARS, and/or MPH dosage was stable
for at least 2 weeks. Subsequently, patients were randomly
allocated to one of the two treatment groups, when the MPH
medication was stabilized at their optimum dose but still show
clinically significant symptoms (CAARS > 20). Allocation to
treatment groups was done according to a stratified block
randomization [strata: age and sex; see (42)]. As indicated
by previous therapeutic studies no other variables are known
to be of importance in randomization. The treatment group
received in addition to MPH a psychotherapeutic treatment.
It consisted of maximum 12 therapeutic sessions. The control
group received clinical management thatmeant the same number
of contacts as the psychotherapy group. However, these contacts
were focused on pharmacotherapy. The patients were asked
about symptoms and any possible side effects. Specific cognitive-
behavioral interventions may not be performed during these
contacts.
At the same time point, baseline evaluation was done. After
completion of therapeutic interventions, a post-study evaluation
was done. Nine months later, a follow-up assessment of outcome
variables was performed to investigate the sustainability of
treatment responses. All ratings were conducted by independent
trained clinical psychologists who did not know which
participants belong neither to the psychotherapy nor to the
clinical management group.
The psychotherapeutic treatment was performed by trained
psychologists with certification in clinical psychology and
extended experience in CBT. The effective use of manual-
based treatments must be preceded by adequate training (43).
Therefore, prior to the start of the study, a 5 days’ workshop
was performed by the principal investigators to train the
involved psychotherapists. The proper use of a manual-based
therapy requires flexible application and ongoing supervision
(43). Therefore, all therapists received supervision on a
regular base. The supervisor examined treatment adherence
and the quality of delivery by continuous supervision.
Furthermore, the supervisor supported the therapists if
problems rose.
FIGURE 1 | Study design and procedure (baseline, pre, post, and follow-up evaluation). MED, Medication; CBT, Cognitive-behavioral therapy; SCM, Standard clinical
management; 1Patient(s) refused further participation.
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The medication was done at the Outpatient Department of
Psychiatry of the UPC by a psychiatrist who had experiences in
treating adult ADHD.
Assessment Instruments
Because of the various impairments in ADHD patients
multidimensional clinical diagnostic instruments were
applied. Apart from the confirmation of the diagnosis and
the recognition of possible comorbid diagnosis, we aimed
to use a multimodal approach (44). We had to consider
different sources of data (e.g., patient, independent rater) and
different functional ranges (e.g., experiences, behavior, feelings,
working capacity). Details about the instruments are described
below.
Classification
In order to verify the diagnosis and to diagnose comorbid
disorders internationally well-established diagnostic interviews
were applied:
Structured clinical interview for DSM-IV [SCID-I and
SCID-II; German version (45, 46)]
Structured interview to assess disorders according to DSM-
IV Axis-I (e.g., affective disorders) und Axis-II disorders
(personality disorders); used to assess comorbid disorders,
administered only at pre-treatment.
Conners’ adult ADHD diagnostic interview for DSM-IV
[CAADID; (47)]
Structured interview based on the DSM-IV criteria and used
for assessing diagnosis retrospectively or confirming a currently
obvious disorder.
ADHD Symptomatology
With respect to the determination of the pathology there is
no generally accepted instrument until now which could be
considered as a gold standard (48). Therefore, those instruments
have been selected which were applied in studies before, in order
to assure comparability, reliability, and validity.
Conners’ adult ADHD rating scale [CAARS; (49)]
Eighteen items rating scale according to the DSM-IV criteria;
four-point rating scale (severity or frequency of the symptoms),
clinician administered.
Conners’ ADHD adult rating scale self-report short version
[CAARS-S:S; (49)]
Twenty-six items rating scale based on DSM-IV criteria.
Conners’ adult ADHD rating scale observer long version
[CAARS-O:L; (49)]
Sixty-six items; four-point rating scale (severity or frequency
of the symptoms), scoring: inattention/memory problems,
hyperactivity/restlessness, impulsivity/emotional lability,
problems with self-concept, DSM-IV inattentive symptoms,
DSM-IV hyperactive symptoms, DSM-IV ADHD symptoms
total, ADHD index.
Wender-Reimherr adult attention deficit disorder rating
scale [WRAADDS; German version (50)]
Structured interview according to the criteria of Paul H. Wender;
seven syndromes (inattention, hyperactivity/restlessness,
impulsivity, disorganization, affective lability, stress intolerance,
temper), more adequate to assess the symptomatology in adults.
ADHD self-rating behavior questionnaire [ADHD-SR; (51)]
Twenty-two items self-rating scale; 18 items according to DSM-
IV/ICD-10; 4 items to assess aspects like impairment, beginning
of symptomatology.
Impairment and Quality of Life
ADHD symptomatology is always related to more or less
remarkable impairments in different functional areas of life.
Despite significant impairments related to adult ADHD, little
is known about how ADHD symptomatology and functional
impairments impact quality of life in patients with this disorder
[see (52, 53)]. Especially in the case of chronically progressing
disorders, such as for instance ADHD, this is of great significance
and has to be assessed. The following questionnaires were
applied:
Sheehan’s disability scale [SDS; (54)]
Global self-rating scale to assess in work, social life or leisure
activities and home-life or family responsibilities.
Adult attention-deficit/hyperactivity disorder quality-of-life
scale [AAQol; (52)]
Twenty-nine items self-rating scale; four domains: life
productivity, psychological health, relationships, life outlook.
General perceived self-efficacy scale [SWE; (55)], SWE
The SWE is a unidimensional scale containing 10 items which are
answered on a four-point scale.
Rosenberg self-esteem scale [RSES; (56)]
The RSES is a unidimensional scale containing 10 items which
measure “global self-esteem.” Each of the 10 items is answered
on a four-point scale.
Attitudes to Treatment and Quality of Therapeutic
Process
Psychotherapy motivation questionnaire [Fragebogen zur
Psychotherapiemotivation (FMP)]
The questionnaire by Schneider et al. (57) was applied to
evaluate therapeutic attitude. The FMP covers several
dimensions: experience of illness, explanation of illness,
treatment expectation, and attitude to psychotherapy.
Bern post session report (58)
The questionnaire addresses central aspects of the therapeutic
process. The scale, containing 29 items, is filled out by the patient,
respectively, the therapist. The following areas are covered:
progress within the therapy sessions, progress outside the therapy
sessions, quality of therapy relation, therapy satisfaction, and
emotion in the therapy. The function of this questionnaire is to
register the progression of the therapy and eventually to provide
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more details about the interpretation of the results found in this
study.
Medication
All subjects received a standard treatment with MPH which
was administered as follows: initiation of treatment with 20mg
Ritalin R© LA 20mg/day; up-titration of Ritalin R© every fourth day
up to a level of 0.5–1.3 mg/kg bodyweight/day; stabilization of
final dosage for at least 2 weeks and no increase of dosage from
then of more than 10% of the final dosage. If Ritalin R© LA did
not show sufficient clinical effects or was not tolerated Concerta R©
was used as a second choice. The initial dosage was Concerta R© 18
mg/day, followed by an up-titration as outlined above.
No other stimulants apart from long-actingMPHwere used in
the study. No non-stimulant medication was initiated. Subjects
on non-stimulant medication with a known effect on ADHD
symptoms could participate in the study if they fulfilled the
following conditions: stable dosage for the last 3 months previous
to baseline investigation, sufficient remaining symptoms for
ADHD diagnosis. In these subjects MPH was administered in
addition to the existing medication. Subjects on non-stimulant
medication for other medical or psychiatric conditions could
participate if their medication was administered on a stable
dosage for at least 3 months and the underlying disorder is
remitted to a clinically not significant level of symptoms. In
addition, this particular medication must not interfere with
MPH.
As soon as subjects were on a clinically sufficient dosage
of MPH and on a stable level for at least 2 weeks, they were
randomized to either multimodal therapy or medication alone.
At the end of the study there was a short clinical check-up again
and adequacy of medication was controlled again. Afterwards
subjects were referred to their physicians or to a specialist for
ADHD if they wished to continue treatment.
The main outcome measure concerning initiation and dosage
adjustment of MPH was a reduction of 30% or more in the sum
score of the investigator-rated CAARS. As soon as patients reach
this level of individual reduction in sum scores their dosage was
not increased any further. If subjects remained stable on this
dosage for at least 2 weeks they were randomized to one of the
two treatment groups in the study.
Psychotherapeutic Treatment Program
The psychotherapeutic program was a cognitive-behavioral
program designed for single-settings and contained several
modules which were summarized in a standardized manual
(see Table 1). The selection and composition of the modules
were directed by the following criteria [see (59)]: ADHD
pathology in adulthood, as outlined by Wender (60) or Wilens
and Dodson (16); already published therapeutic approaches (61,
62); general principles of CBT; analysis of problem areas of more
than 400 own patients as well as our own clinical experience in
the treatment of ADHD patients.
The full therapy program consisted of a minimum of 10
weekly sessions (including one final session), and a maximum
of 12 sessions. The manual contained a description of each
session of the therapeutic interventions as well as general advices.
(e.g., example of engagement with the patients). Apart from the
first two sessions the weekly therapy sessions were identical in
structure: discussion of homework given in the previous session,
presenting the theme of the current session, presentation of new
homework.
Discussing homework of the previous session aimed to
evaluate therapeutic progress and to control whether therapeutic
strategies were used in daily life or not. If problems raised it was
necessary to identify the cause and to work out realistic solutions
with the patient. The presentation of the content of each session
should provide a clear structure for the patient. This seems to
be extremely important in the treatment of ADHD (23, 26). The
TABLE 1 | Overview of the psychotherapeutic modules.
Psychotherapeutic modules Number of sessions
(each 120min)
Contents and themes
BASIC MODULES (B)
B 1 Psychoeducation and behavior
analysis
2 • Psychoeducation about ADHD in adulthood
• Information about vulnerability factors relative to ADHD pathology
• Analysis of the specific behavioral problems
• Looking for strategies that have been successful up to now
B 2 Cognitive therapy 4 • Therapy model and introduction to cognitive therapy
• Restructuring dysfunctional ADHD-specific cognitions and fundamental beliefs
or rather cognitive schemas, cognitive distortions and errors
B 3 Final and preventive session 1 • Summary of helpful strategies
• Placing emphasis on the necessity of doing exercises continuously
• Strategies supporting the self-evaluation of further improvements
OPTIONAL MODULES (O)
O 1 Organization 1 • Acquisition of organizing and planning skills
O 2 Procrastination 1 • Handling procrastination of duties and activities
O 3 Learning 1 • Acquisition of learning skills
• Training concentration
O 4 Impulsiveness 1 • Handling impulsiveness, emotional overreactivity and low control of affect
O 5 Partnership 1 • Improvement of communication and problem-solving skills in close relationships
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most important part of each session was the main topic of the
module in question. Homework was always derived from this
main topic. Patients were asked to do their homework and write
down their experience with the tasks they had to fulfill.
Practical parts of the therapy sessions were: exercises, role
plays, hand-outs, and work sheets. The therapy set consisted of
different basic (B 1–3) and optional modules (O 1–5). Whereas,
the basic modules were used with all patients, the application
of the optional modules depended on the conclusions from the
individual analysis of behavior which meant that the specific
problems of the patient were taken into account for the choice
of optional modules.
Standard Clinical Management
Concerning standard clinical management (SCM) we refer to
the NIMH-depression study (63). In the NIMH-study a 30-
min medication counseling on effects and side effects was
administered to patients of the control group by a psychiatrist.
The frequency was the same as in the experimental group. Elkin
(64) described it as “minimal supportive therapy” which is more
than a waiting group.
In our study patients in the control group received
SCM consisting of medication counseling administered by a
psychiatrist. SCM was administered weekly by 30min sessions.
The elements of SCM were written down in a manual to guide
the psychiatrist through the standardized procedure similar as
described by Fawcett et al. (65).
In SCM apart from evaluating the general state of health and
mind as well as effects and side effects of medication, the pulse
rate, blood pressure and weight were measured. Also the CAARS
was administered to assess the course of ADHD with ongoing
medication. The patient was encouraged to report difficulties he
experienced since the last visit but he was instructed that he will
not receive any psychotherapeutic interventions. The psychiatrist
listened and responded empathically but restricted counseling to
the above-mentioned items. In the case of severely aggravating
difficulties or even suicidality the psychiatrist was obliged to react
to the patient’s problems in the same way as if the patient was not
a study participant. If additional psychotherapeutic counseling,
additional medication, or even hospitalization became necessary
the patient was withdrawn from the study and received the usual
clinical treatment. This procedure ascertained that patient’s needs
were fully respected and dangerous situations were avoided.
Psychiatrists received a didactic training in SCM for at least half
a day.
Data Analysis
For all statistical analyses, SPSS (Version 24.0) were used. In a
first step, descriptive statistics were determined, and the sample
was explored for possible group differences at the baseline.
To accurately answer the main hypothesis that a treatment of
ADHD with CBT plus medication (MED) would provide a
higher efficacy than SCM plus MED, in a second step analyses
of variance (ANOVA) with the between-factor (group: CBT +
MED vs. SCM + MED) and the within-factor (time: pre, post,
follow-up), and—for the main hypothesis most relevant—the
interaction term (group × time) were conducted. To provide
robust outcomes, normalized latent variables were extracted
through principal component analysis for the total scores and the
different domains of ADHD assessed via CAARS, CAARS-S:S,
CAARS-O:L, WRAADDS, and ADHD-SR and for impairments
measured by SDS, AAQol, SWE, and RSES. Since this data
set does not contain a suitable number of cases for such a
procedure to produce stable results, the general data set of the
ADHD Special Consultations Unit of the Outpatient Department
of the UPC was used to provide the weights of the different
subscales. For further information on this data set see [(5), (7) or
(66)]. Finally, to gain broader insight in the therapy efficacy, the
relations of CBT process characteristics within this group and the
symptom and impairment improvements were examined using
Spearman’s correlations.
RESULTS
Participants Characteristics
The sample of the study consisted in 24 (55.8%) males and 19
(44.2%) females. The subjects were between 18 and 49 years of
age (M = 31.91, SD = 8.41). Finally, all included patients (N
= 43) were randomized into the following two groups: Group
1: CBT + MED (n = 20, 46.5%); and Group 2: SCM + MED
(n = 23, 53.5%). The distribution of the sociodemographic
information and the current clinical characteristics, the symptom
and impairment levels of these groups at time of the first patient’s
contact are shown in Table 2. No significant group differences at
baseline were found.
Extracting Latent Variables for ADHD
Symptoms and Impairment
To provide robust outcomes measures, firstly latent variables
were formed. For the general ADHD symptoms a factor analysis
was executed; to include only the shared variances of the different
perspectives within the different ADHD scales the principle axis
method was used. A solution with one component was found
(λ = 3.21), explaining 64.20% of the total variance. The same
procedure was used for each subdomain where also solutions
with one component were repeatedly found (λ = 1.85–3.51),
explaining 56.36% of the variance in the subscales of inattention,
70.19% of hyperactivity, 61.71% of impulsivity, and 61.59% of
emotional symptoms. For the impairment scales a solution with
two factors was found (λi1 = 3.98 and λ i2 = 1.65), explaining
56.25% of the variance. On the first rotated factor all subscales of
AAQoL (0.566–0.681) and the subscales of SDS for family (0.542)
and work (0.398) loaded highly; while the subscale of SDS for
leisure (0.318) and social contacts (0.319) loaded on both factors
medium high. Subscales of RSES and SWE loaded both highly
on the second factor (0.641–0.862). Those two factors correlated
slightly (r = 0.362).
Symptom Level Changes and Impairment
Changes Between the Two Treatment
Groups
To test the main hypothesis ANOVAs between subjects with CBT
+MED and SCM+MEDwere conducted with the within factor
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TABLE 2 | Sociodemographic and current clinical characteristics of the patients in
the two treatment groups.
CBT + MED
n = 20
SCM + MED
n = 23
Test values p
Gender χ2
(1)
= 0.01 0.920
Male 11 13
Female 9 10
Age [M (SD)] 34.05 (9.34) 30.04 (7.21) F (1) = 2.52 0.120
Relational status χ2
(3)
= 2.80 0.424
Single 10 13
Married/relationship 9 6
Divorced 1 3
Separated 0 1
Education χ2
(3)
= 1.36 0.714
Secondary School 11 13
College 7 8
University 2 2
Employment χ2
(5)
= 4.12 0.532
Fulltime 5 4
Part-time 4 3
Unemployed 2 2
Student 8 9
Homemaker 0 4
Unemployable 1 1
ADHD
Symptom levels (latent
factors) [M (SD)]
Total 1.32 (0.25) 1.30 (0.27) t(40) = 0.335 0.739
INA 1.41 (0.23) 1.34 (0.24) t(40) = −0.941 0.353
HYP 1.05 (0.31) 1.06 (0.43) t(40) = 0.099 0.922
IMP 1.01 (0.38) 1.03 (0.30) t(40) = 0.125 0.901
ES 1.08 (0.25) 1.18 (0.42) t(34.44) = 0.920 0.364
Impairments (latent factors)
[M (SD)]
IMPAIR 1 2.01 (0.48) 1.97 (0.53) t(38) = −0.722 0.477
IMPAIR 2 −0.14 (0.35) −0.07 (0.40) t(38) = −0.543 0.592
Comorbid disorders
Axis I 2 6 χ2
(1)
= 0.00 0.975
Alcohol abuse 0 1
Cannabis 0/1 1/0
abuse/dependence
Depressive episode 1 1
Social phobia 0 1
Specific phobia 0 1
PTSD 0 1
Axis II 6 2 χ2
(5)
= 6.56 0.256
Avoidant PD 1 2
Obsessive-compulsive PD
1 0
Paranoid PD 1 0
Borderline PD 1 0
Antisocial PD 2 0
Attitude to treatment
(n = 19) [M (SD)]
164.32
(12.74)1
– – –
(Continued)
TABLE 2 | Continued
CBT + MED
n = 20
SCM + MED
n = 23
Test values p
Experience of illness 29.74
(4.20)2
–
Explanation of illness 28.00
(4.86)3
–
Treatment expectation 31.58
(3.02)4
–
Attitude to psychotherapy 75.00
(7.34)5
–
CBT, Cognitive-behavioral therapy; SCM, Standard clinical management; MED,
Medication; M, mean; SD, standard deviation; ADHD, Attention-deficit/hyperactivity
disorder; INA, Inattention; HYP, Hyperactivity; IMP, Impulsivity; ES, Emotional symptoms;
IMPAIR 1/2, Impairment factor 1/2; PTSD, Post-traumatic stress disorder; PD, Personality
disorder; 1t-value, 51; percentile , 54; 2t-value, 45; percentile, 31; 3t-value, 49; percentile,
48; 4t-value, 55; percentile, 69; 5t-value, 53; percentile, 62.
time. Table 3 presents the estimated means of the two different
groups. The analysis of ADHD symptoms showed a statistically
significant main effect of the factor time [F(1, 96) = 83.49, p <
0.001, η2 = 0.723] but not of the factor group [F(1, 32) = 0.01,
n.s.]. Neither did the interaction effect of group and time reach
significance [F(1, 96) = 0.67, n.s.]. The same pattern was also
found for the subdomains of ADHD: inattention, hyperactivity,
impulsivity, and emotional symptoms and also for the two latent
variables of impairment (see Table 4, Figure 2, and Figure 3).
Correlations Between Changes in Core and
Emotional Symptoms of ADHD,
Impairments and Process Characteristics
of the CBT
Spearman’s correlations were carried out to explore the
relationship between CBT process characteristics of the therapy
group (progress within therapy) and the changes in symptom and
impairment levels. Emotion in therapy showed for the symptoms
inattention (ρ = −0.57, p < 0.01), hyperactivity (ρ = −0.60,
p < 0.01), and emotional symptoms (ρ = −0.60, p < 0.01)
high correlations but not for impulsivity (ρ = −0.28, n.s.). The
perceived quality of therapy relation and therapy satisfaction
correlated significantly with the latent factors of impairment
(factor 1: ρ = −0.46, p < 0.01 and ρ = −0.56, p < 0.01; factor
2 ρ = −0.49, p < 0.01 and ρ = −0.57, p < 0.01) but not with
ADHD symptoms. All correlations are displayed in Table 5.
DISCUSSION
The aim of the randomized controlled study was to analyze the
efficacy of multimodal individual therapy (experimental group)
in comparison with medication alone (control group). Whereas,
the experimental group (CBT + MED) attended individual
psychotherapy sessions, the control group (SCM + MED) only
receivedmedication and clinical counseling. The current findings
do not support the notion that CBT outperforms SCM when
added to a pharmacological treatment.
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TABLE 3 | Mean (M) and standard error (SE) of ADHD symptoms and impairment at baseline pre, post, and follow-up evaluation.
CBT + MED SCM + MED
Baseline
(M [SE])
Pre
(M [SE])
Post
(M [SE])
Follow-up
(M [SE])
Baseline
(M [SE])
Pre
(M [SE])
Post
(M [SE])
Follow-up
[M (SE)]
ADHD (Total) 1.35 (0.07) 0.73 (0.08) 0.52 (0.06) 0.67 (0.09) 1.27 (0.06) 0.71 (0.07) 0.59 (0.06) 0.65 (0.08)
INA 1.44 (0.06) 0.70 (0.09) 0.53 (0.07) 0.72 (0.09) 1.35 (0.05) 0.70 (0.08) 0.56 (0.06) 0.64 (0.08)
HYP 1.05 (0.10) 0.66 (0.10) 0.42 (0.08) 0.47 (0.11) 1.00 (0.09) 0.58 (0.09) 0.49 (0.07) 0.52 (0.09)
IMP 1.04 (0.08) 0.60 (0.07) 0.37 (0.07) 0.49 (0.08) 0.98 (0.08) 0.64 (0.07) 0.50 (0.06) 0.54 (0.07)
ES 1.11 (0.09) 0.52 (0.08) 0.51 (0.09) 0.59 (0.09) 1.10 (0.08) 0.65 (0.07) 0.56 (0.08) 0.55 (0.08)
IMPAIR 1 2.07 (0.16) 1.72 (0.17) 1.35 (0.16) 1.32 (0.13) 2.07 (0.15) 1.77 (0.16) 1.24 (0.15) 1.40 (0.12)
IMPAIR 2 −0.09 (0.13) −0.12 (0.14) −0.43 (0.12) −0.51 (0.09) 0.00 (0.12) 0.01 (0.13) −0.57 (0.11) −0.50 (0.08)
Latent factors of the different scales for: ADHD, Attention-deficit/hyperactivity disorder; INA, Inattention; HYP, Hyperactivity; IMP, Impulsivity; ES, Emotional symptoms; IMPAIR 1/2,
Impairment factor 1/2; CBT, Cognitive-behavioral therapy; SCM, Standard clinical management; MED, Medication.
TABLE 4 | ANOVAs of ADHD symptom and impairment level changes between the two treatment groups.
Main effects of time Main effects of group Interactions time × group
F-value η2 F-value η2 F-value η2
ADHD (Total) F (3, 96) = 83.49*** 0.723 F (1, 32) = 0.00 0.001 F (3, 96) = 0.67 0.021
INA F (3, 96) = 91.62*** 0.741 F (1, 32) = 0.20 0.006 F (3, 96) = 0.51 0.016
HYP F (3, 96) = 37.87*** 0.542 F (1, 32) = 0.00 0.000 F (3, 96) = 0.69 0.021
IMP F (3,96) = 60.90*** 0.656 F (1, 32) = 0.18 0.006 F (3, 96) = 1.39 0.042
ES F (3,96) = 45.64*** 0.588 F (1, 32) = 0.04 0.005 F (3, 96) = 0.88 0.027
IMPAIR 1 F (3, 72) = 14.16*** 0.371 F (1, 24) = 0.00 0.000 F (3, 72) = 0.18 0.007
IMPAIR 2 F (3, 72) = 10.44*** 0.303 F (1, 24) = 0.01 0.003 F (3, 72) = 0.56 0.023
Latent factors of the different scales for: ADHD, Attention-deficit/hyperactivity disorder; INA, Inattention; HYP, Hyperactivity; IMP, Impulsivity; ES, Emotional symptoms; IMPAIR 1/2,
Impairment factor 1/2; ***p < 0.001.
The different analyses show a statistically decrease of ADHD
symptoms during the time (baseline, pre- and post-treatment)
and an increase of symptoms in the follow-up. However, both
groups did not differ significantly in the ratings of ADHD
symptoms. The same results were found for the single ADHD
domains (inattention, hyperactivity, impulsivity, and emotional
symptoms) and also for impairment in daily life. The assessment
of the quality of therapy in the therapy group showed that
inattention, hyperactivity, and emotional symptoms correlated
high and significantly with the domain emotion in therapy.
However, the perceived quality of therapy relation and therapy
satisfaction correlated significantly with impairments but not
with ADHD symptoms.
According to guidelines, psychopharmacological treatment
is currently considered as first-line treatment for adults in
ADHD (12, 13, 19, 67). However, the course of the disorder
seems to justify additional psychological interventions for
several reasons: Some symptoms seem to be more accessible
by psychotherapy (e.g., organizational and social behavior)
whereas other symptoms respond more readily to medication
(e.g., attention, emotional instability) (11). In addition, the
full remission of ADHD symptoms is not always achieved
with pharmacotherapy (68). Some of the specific impairments,
viewed as consequences of the chronic course of ADHD
from early childhood into the adult life span, resist to
FIGURE 2 | Mean of latent variables: ADHD symptoms changes over time
(baseline, pre, post, and follow-up evaluation). CBT, Cognitive-behavioral
therapy; SCM, Standard clinical management; MED, Medication.
pharmacology, and demand a treatment option. Finally, either
due to skepticism toward medication or due to lack of tolerance
of psychopharmacological interventions (19, 69), it seems to
be evident that psychotherapy could help ADHD patients to
treat particularly issues in cognitive schemas, organization,
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FIGURE 3 | Mean of latent variables: ADHD symptoms (inattention, hyperactivity, impulsivity, and emotional symptoms) and impairments changes over time (baseline,
pre, post, and follow-up evaluation). CBT, Cognitive-behavioral therapy; SCM, Standard clinical management; MED, Medication.
TABLE 5 | Spearman’s correlations between changes in core and emotional symptoms of ADHD, impairments and process characteristics of the CBT.
INA HYP IMP ES IMPAIR 1 IMPAIR 2
Progress within therapy −0.343 −0.353 −0.225 −0.142 −0.386 −0.460*
Progress outside therapy −0.379 −0.278 −0.265 −0.204 −0.374 −0.415
Quality of therapy relation −0.309 −0.363 −0.198 −0.137 −0.464* −0.494*
Therapy satisfaction −0.293 −0.408 −0.242 −0.155 −0.560** −0.568**
Emotion in therapy −0.568** −0.603** −0.279 −0.613** −0.400* −0.412*
Difference of post to baseline latent factors INA, Inattention; HYP, Hyperactivity; IMP, Impulsivity; ES, Emotional symptoms; IMPAIR 1/2, Impairment factor 1/2; *p < 0.05; **p < 0.01
(one-tailed).
procrastination, learning, emotional regulation, self-esteem,
and/or partnership.
A multimodal approach to the treatment of ADHD is
recommended by international guidelines (12, 13). CBT may
be a supplement to psychopharmacological treatments, but
more research is needed to establish the effectiveness of this
treatment. The findings of the small number of randomized
controlled studies in this area and particularly in individual
psychotherapy for adults with ADHD have reported mixed
findings.
In line with the findings of the current study are the results
of Philipsen et al. (70) who however amongst others evaluated
the efficacy of CBT group + MED compared with individual
clinical management + MED. The outcomes showed that the
CBT group was not more effective than the individual clinical
management. Two studies similar to the present study compared
CBT + MED vs. MED alone (35, 62) contrasting with the
results of the here presented trial. In Safren et al. (62) and
Emilsson et al. (35) CBT + MED was more effective than MED
alone reducing the core ADHD symptoms significantly in fact
in clinician and self-rating. In addition, Emilsson et al. (35)
found in the multimodal group a significant reduction of self-
reported inattention, but no significant effect in self-reported
hyperactivity-impulsivity.
An explanation for our results may be that in our sample
the medication responded very good. All patients received
Ritalin R© LA. The second choice of medication (Concerta R©)
was not used because all patients responded very good to
Ritalin R© LA. The reduction of ADHD symptoms from baseline
to pre-treatment assessment counted for both groups 50%. In
comparison Stevenson et al. (38) reported a reduction of ADHD
symptoms of 37% (baseline to pre-treatment) and at post-
treatment the statistically significant reduction was 55%. Safren
et al. (24) included patients with all sort of ADHD medication
and in contrast to our study medication discontinuation did not
lead to a dropout. Also Solanto et al. (71) reported the change
of medication in their trial. No study measured and controlled
the response of medication, arising the question if patients with
a low response to pharmacological treatment benefit more from
CBT. In general, more attention to medication should be paid in
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further studies, to understand in detail the benefit of medication
reducing ADHD symptoms and in combination to CBT (17, 40).
Studies with an additional group—CBT without medication—
could help to analyze better the role of medication as well as of
CBT.
In our study patients in the control group received SCM
which elements were standardized and noted in a manual to
guide the psychiatrist performing practice care in a professional,
emphatical, and optimal way. As a consequence, SCM as an
established and well-known procedure in psychiatric settings,
in combination with medication, showed similar outcomes
than the here presented standardized ADHD psychotherapy
program. This program may not have been sufficiently effective
to outperform SCM.
Whereas, every single psychotherapeutic session was video
recorded and supervised, the SCM sessions unfortunately
were neither recorded nor supervised. The adherence to the
SCM protocol was so not controlled. However, these data
could help to understand the interaction between medication,
psychotherapy, and attitude to treatment in the different groups.
In a smaller sample of the psychotherapy group we analyzed
27 randomly selected psychotherapy sessions of nine patients
with the aim to evaluate the treatment adherence of the involved
psychotherapists: Two trained independent psychologists rated
on the basis of the Cognitive Therapy Adherence and Competence
Scale [CTACS; (72)] the video recordings. The adherences of the
three involved psychotherapists to the CBT program (M = 5.82
[SD = 0.004]–M = 5.66 [SD = 0.19]) and quality of therapy (M
= 5.52 [SD = 0.22]–M = 5.72 [SD = 0.06]) were all above the
cutoff of the CTACS (M ≥ 4) which can be interpreted as a good
adherence.
Our ADHDpsychotherapy programwas based on CBT theory
and models. Although the elements of our program derive from
established and reliable techniques which have been adapted
to the special need of ADHD patients, a pilot study may have
identified less effective therapeutic interventions giving us the
possibility to adjust our program. The therapy set consisted of
different basic and optional modules. This set of modules was
based on the diagnostic criteria of ADHD and the corresponding
results from the literature (60–62). Whereas, the basic modules
were used with all patients, the application of the optional
modules depended on the conclusions from the individual
analysis of behavior which meant that the specific problems of
the patient were taken into account for the choice of optional
modules. However, this procedure signifies that not all patients
in the CBT + MED group passed through the same modules
making it now difficult to filter the psychotherapeutic elements
that are not enough effective to outperform SCM. Future research
could aim to understand which components of CBT are effective
in the treatment of ADHD (40).
The standardized ADHD specific CBT program consisted in
10–12 sessions, each lasting 120min. While the treatment period
might be too short to ensure that patients continued to use
the new learned skills, the length of each session might be too
long. Due to the compact and short treatment patients might be
not able to properly develop new functional strategies, enduring
behavior, and thinking patterns.
A further explanation for our results may be found in the
problem activation (73) and self-awareness (74) taken place
in psychotherapies. Although the aim of the psychotherapy in
this study was also to activate the resources of every patients,
it is important to note that only the patients of the CBT +
MED group were confronted with their problems, weakness,
and impairments. Lambert (75) explains that up to 5–10% of
patient’s symptoms during treatment increase and the length
of the psychotherapeutic intervention in our study may be too
short to reduce this increase of symptoms. Problem activation
can trigger all kinds of protective and resistive mechanisms
preventing change (73). Self-awareness may be accompanied by
increased distress or lower self-esteem (74).
The current study focused on the symptom reduction of
ADHD in adults. The structure of the CBT program was a
central aspect in the standardized manual. The assessment of the
quality of therapy in the therapy group showed that the factor
emotion in therapy correlated with ADHD symptoms (except
impulsivity). It seems to be beneficial to activate emotion in
the therapy session. Furthermore, and more relevant, may be
the findings that the quality of relation and therapy satisfaction
correlated with impairments. The focus of impairments is crucial
in psychotherapy with ADHD patients because of the severe
difficulties of those patients on daily functioning (9, 10). ADHD
symptoms increase the risk of functional impairments making
it important to address this in psychotherapy. The quality of
relation between psychotherapist and patient (76) is an important
effect of the psychotherapy. Meta-analyses could show that
10% of the variance of the psychotherapy’s success is explained
of the therapeutic relationship and seems to be the most
important component in psychotherapy (77). Grawe (76) stated
that interpersonal relationships are important patient’s resources
in psychotherapy because low self-esteem and self-efficacy can be
affected positively by relationships and consequently influence
the process of therapy (78). Thus, future ADHD psychotherapy
studies should consider more these issues.
Limitations
The aim of our study was to analyze the data of more
patients. Unfortunately, it was not possible to include more
patients during the defined study time. The small size of
both treatment conditions was especially relevant in the
questionnaires measuring impairments. The number of filled
questionnaires especially in the follow-up evaluation were too
small. The package of questionnaires may be too large and must
be adjusted for future studies.
Attitude to treatment was only measured and controlled in
the CBT + MED group and also only with one questionnaire.
However, this aspect is important in psychotherapeutic as well
as in psychopharmacological treatments (75) and should be
addressed in future studies. It remains unclear in our study if the
patients of the SCM+MED group were poor or more motivated
or had positive beliefs regarding medication. A high attitude to
treatment could result in better treatment outcomes and so being
able to outweigh the efficacy of psychotherapy.
Although the two groups did not show a statistically
significant difference in comorbid disorders (Axis I and II),
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there were more patients with a comorbid personality disorder
(Axis II) in the CBT + MED group. The presence of these
comorbidities might have had a stronger impact on the treatment
progress and effects of the experimental group. In future research
the control of this aspect is mandatory.
CONCLUSION
The present randomized controlled trial is one of the few
studies focusing on ADHD multimodal individual therapy. The
here developed standardized ADHD specific CBT program does
not suggest that CBT augments significantly the reduction of
ADHD symptoms. The CBT programwas not able to outperform
SCM which is a well-known psychiatric procedure. In further
study the role of medication, CBT components, techniques,
as well as modules, attitude/adherence to treatment in ADHD
psychotherapy and further possible side effects in CBT should be
paid more attention. This could help to understand the impact of
CBT to reduce ADHD symptoms and functional impairments.
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